{"organizations": [], "uuid": "96bbbb0f3e4d9065ac91124d528b5cb75d1dae09", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180403.html", "section_title": "Archive News &amp; Video for Tuesday, 03 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-tonix-pharma-ready-to-file-for-app/brief-tonix-pharma-ready-to-file-for-approval-of-ptsd-treatment-in-2019-based-on-study-data-idUSASC09UMW", "country": "US", "domain_rank": 408, "title": "BRIEF-Tonix Pharma Ready To File For Approval Of PTSD Treatment In 2019 Based On Study Data", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.487, "site_type": "news", "published": "2018-04-03T19:36:00.000+03:00", "replies_count": 0, "uuid": "96bbbb0f3e4d9065ac91124d528b5cb75d1dae09"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-tonix-pharma-ready-to-file-for-app/brief-tonix-pharma-ready-to-file-for-approval-of-ptsd-treatment-in-2019-based-on-study-data-idUSASC09UMW", "ord_in_thread": 0, "title": "BRIEF-Tonix Pharma Ready To File For Approval Of PTSD Treatment In 2019 Based On Study Data", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "tonix pharmaceuticals holding corp", "sentiment": "negative"}, {"name": "pharmaceuticals holding corp", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 3 (Reuters) - Tonix Pharmaceuticals Holding Corp :\n* TONIX PHARMACEUTICALS ACHIEVES 50 PERCENT ENROLLMENT IN PHASE 3 TRIAL OF FDA-DESIGNATED BREAKTHROUGH THERAPY TONMYA® (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) FOR THE TREATMENT OF PTSD\n* TONIX PHARMACEUTICALS HOLDING CORP - ‍TOPLINE RESULTS OF ABOUT 550 PARTICIPANTS WITH MILITARY-RELATED PTSD EXPECTED IN Q4 2018​\n* TONIX PHARMACEUTICALS HOLDING - ‍PHASE 3 HONOR STUDY ENROLLMENT CONTINUES & INTERIM RESULTS OF FIRST 50 PERCENT OF PARTICIPANTS EXPECTED IN Q3 2018​\n* TONIX PHARMACEUTICALS - EVIDENCE FROM PHASE 2 STUDY OF TONMYA SHOWED POTENTIAL IMPROVEMENT OVER EXISTING THERAPIES USED TO TREAT MILITARY-RELATED PTSD​\n* TONIX PHARMACEUTICALS HOLDING CORP - CO IS READY TO FILE NDA FOR TONMYA FOR TREATMENT OF PTSD IN 2019 IN EVENT OF A PERSUASIVE OUTCOME OF HONOR STUDY​ Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-03T19:36:00.000+03:00", "crawled": "2018-04-04T12:21:19.061+03:00", "highlightTitle": ""}